I-MAB-SPONSORED ADR (IMAB) Stock Price, Quote, News and Overview
NASDAQ:IMAB - Nasdaq - US44975P1030 - ADR - Currency: USD
IMAB Quote, Performance and Key Statistics
NASDAQ:IMAB (4/17/2025, 8:00:02 PM)
0.8452
+0 (+0.46%)
The current stock price of IMAB is 0.8452 USD. In the past month the price decreased by -1.82%. In the past year, price decreased by -53.04%.
IMAB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About IMAB
Company Profile
I-Mab operates as a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel or differentiated biologics to treat diseases with unmet medical needs, particularly cancers and autoimmune disorders. The company is headquartered in Rockville, Maryland and currently employs 220 full-time employees. The company went IPO on 2020-01-17. The firm is focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer. Its pipeline strategy is to build a risk-controlled clinical-stage pipeline with a focus on novel or highly differentiated biologics. The Company’s pipeline includes Uliledlimab (TJD5), Givastomig (TJ-CD4B), and Ragistomig (TJ-L14B). Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Uliledlimab offers clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Givastomig is designed as a bispecific antibody to target Claudin 18.2-positive tumor cells, with conditional activation of pro-immune 4-1BB in the tumor microenvironment. Ragistomig is designed as a bispecific antibody to address PD-L1 resistant tumors.
Company Info
I-MAB-SPONSORED ADR
Suite 400, 2440 Research Blvd
Rockville MARYLAND 201210 US
CEO: Joan Huaqiong Shen
Employees: 34
Company Website: https://www.i-mabbiopharma.com/
Investor Relations: https://ir.i-mabbiopharma.com/
Phone: 13016702800
I-MAB-SPONSORED ADR / IMAB FAQ
What is the stock price of I-MAB-SPONSORED ADR today?
The current stock price of IMAB is 0.8452 USD. The price increased by 0.46% in the last trading session.
What is the ticker symbol for I-MAB-SPONSORED ADR stock?
The exchange symbol of I-MAB-SPONSORED ADR is IMAB and it is listed on the Nasdaq exchange.
On which exchange is IMAB stock listed?
IMAB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for I-MAB-SPONSORED ADR stock?
9 analysts have analysed IMAB and the average price target is 5.1 USD. This implies a price increase of 503.41% is expected in the next year compared to the current price of 0.8452. Check the I-MAB-SPONSORED ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is I-MAB-SPONSORED ADR worth?
I-MAB-SPONSORED ADR (IMAB) has a market capitalization of 68.36M USD. This makes IMAB a Micro Cap stock.
How many employees does I-MAB-SPONSORED ADR have?
I-MAB-SPONSORED ADR (IMAB) currently has 34 employees.
What are the support and resistance levels for I-MAB-SPONSORED ADR (IMAB) stock?
I-MAB-SPONSORED ADR (IMAB) has a resistance level at 0.86. Check the full technical report for a detailed analysis of IMAB support and resistance levels.
Is I-MAB-SPONSORED ADR (IMAB) expected to grow?
The Revenue of I-MAB-SPONSORED ADR (IMAB) is expected to decline by -100% in the next year. Check the estimates tab for more information on the IMAB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy I-MAB-SPONSORED ADR (IMAB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of IMAB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of IMAB, evaluating the profitability, health, valuation and growth aspects
- I-MAB-SPONSORED ADR (IMAB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- I-MAB-SPONSORED ADR (IMAB) Sales and EPS estimates to see what analysts future expectations are.
- I-MAB-SPONSORED ADR (IMAB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- I-MAB-SPONSORED ADR (IMAB) Insider and Institutional Ownership to learn about the owners and their transactions.
- I-MAB-SPONSORED ADR (IMAB) Stock Chart to make your own analysis
- I-MAB-SPONSORED ADR (IMAB) Latest news and press-releases to stay up to date.
Does I-MAB-SPONSORED ADR (IMAB) stock pay dividends?
IMAB does not pay a dividend.
When does I-MAB-SPONSORED ADR (IMAB) report earnings?
I-MAB-SPONSORED ADR (IMAB) will report earnings on 2025-08-26.
What is the Price/Earnings (PE) ratio of I-MAB-SPONSORED ADR (IMAB)?
I-MAB-SPONSORED ADR (IMAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-18.12).
What is the Short Interest ratio of I-MAB-SPONSORED ADR (IMAB) stock?
The outstanding short interest for I-MAB-SPONSORED ADR (IMAB) is 3.56% of its float. Check the ownership tab for more information on the IMAB short interest.
IMAB Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IMAB. When comparing the yearly performance of all stocks, IMAB is a bad performer in the overall market: 86.07% of all stocks are doing better.
IMAB Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to IMAB. While IMAB seems to be doing ok healthwise, there are quite some concerns on its profitability.
IMAB Financial Highlights
Over the last trailing twelve months IMAB reported a non-GAAP Earnings per Share(EPS) of -18.12. The EPS increased by 45.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -56.09% | ||
| ROE | -85.31% | ||
| Debt/Equity | 0.02 |
IMAB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to IMAB. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 92.19% and a revenue growth -100% for IMAB